Roots Analysis has done a detailed report on Antibody Drug Conjugates Market (5th Edition), 2019-2030.” , covering various important aspects of the industry and identifying key future growth opportunities.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Key Market Insights
§ Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
§ Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
§ The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
§ In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
§ A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
§ Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
§ Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
§ The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
§ In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
§ Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
§ Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
§ Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
§ With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
§ The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
4.3. ADC Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Number of ADC Therapeutics
4.4. ADC Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Size and Target Indication
4.5. Novel Drug Conjugates
5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and Future Outlook
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and Future Outlook
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximab soravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and Future Outlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and Future Outlook
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin
5.8.3.2.1. Drug Overview
5.8.3.2.2. Mechanism of Action
5.8.3.2.3. Clinical Development Status
5.8.3.2.4. Key Clinical Trial Results
5.8.4. Recent Developments and Future Outlook
5.9. Roche / Genentech
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. KADCYLA®
5.9.3.1.1. Drug Overview
5.9.3.1.2. Mechanism of Action
5.9.3.1.3. Clinical Development Status
5.9.3.1.4. Key Clinical Trial Results
5.9.3.2. RG-7596
5.9.3.2.1. Drug Overview
5.9.3.2.2. Mechanism of Action
5.9.3.2.3. Clinical Development Status
5.9.3.2.4. Key Clinical Trial Results
5.9.4. Recent Developments and Future Outlook
5.10. Seattle Genetics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. ADCETRIS®
5.10.3.1.1. Drug Overview
5.10.3.1.2. Mechanism of Action
5.10.3.1.3. Clinical Development Status
5.10.3.1.4. Key Clinical Trial Results
5.10.3.2. SGN- LIV1A
5.10.3.2.1. Drug Overview
5.10.3.2.2. Mechanism of Action
5.10.3.2.3. Clinical Development Status
5.10.3.2.4. Key Clinical Trial Results
5.10.4. Recent Developments and Future Outlook
5.11. Synthon
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. SYD985 / Trastuzumab Duocarmazine
5.11.3.1.1. Drug Overview
5.11.3.1.2. Mechanism of Action
5.11.3.1.3. Clinical Development Status
5.11.3.1.4. Key Clinical Trial Results
5.11.4. Recent Developments and Future Outlook
5.12. Other Companies
5.12.1. Bayer HealthCare
5.12.1.1. Company Overview
5.12.1.2. Financial Information
5.12.1.3. Pipeline Overview
5.12.1.4. Recent Developments and Future Outlook
5.12.2. Biotest Pharmaceuticals
5.12.2.1. Company Overview
5.12.2.2. Financial Information
5.12.2.3. Pipeline Overview
5.12.2.4. Recent Developments and Future Outlook
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADC Therapeutics for Leukemia / Lymphoma
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma
6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer
6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer
6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer
6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer
6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer
6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer
6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Prostate Cancer
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology
7.3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on ADCETRIS®
7.3.1.2. Experts on KADCYLA®
7.3.1.3. Experts on MYLOTARG™
7.3.1.4. Experts on Other ADCs
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
7.6. Most Active Key Opinion Leaders
7.6.1. Profile: KOL A (Celgene)
7.6.2. Profile: KOL B (Western Regional Medical Center)
7.6.3. Profile: KOL C (MedStar Washington Hospital Center)
7.6.4. Profile: KOL D (Cancer Institute and Hospital)
7.6.5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
7.6.6. Profile: KOL F (Hopital Tenon)
7.6.7. Profile: KOL G (Cleveland Clinic)
8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Competitiveness Analysis: Key Clinical Targets for ADCs
8.3.1. Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider Web Analysis
8.4. Competitiveness Analysis: Key Preclinical Targets for ADCs
8.4.1. Two-Dimensional Scatter Plot Analysis
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. ADC Therapeutics: List of Partnerships and Collaborations
9.3.1 Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnerships
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. ADC Therapeutics: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. High Value Deals: Analysis by Year
10.3.4. Analysis by Type of Funding
10.3.5. Most Active Players
10.3.5.1. Analysis by Number of Funding Instances
10.3.5.2. Analysis by Amount Invested
10.4. Concluding Remarks
11. PATENT ANALYSIS
11 Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. ADC Therapeutics: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geographical Location
11.3.3. Analysis by CPC Classification
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Industry
11.3.6. Leading Players: Analysis by Number of Patents
11.4. ADC Therapeutics: Patent Benchmarking Analysis (Industry Players)
11.4.1. Analysis by Patent Characteristics
11.4.2. Analysis By Geographical Location
11.5. ADC Therapeutics: Patent Valuation Analysis
12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: List of Academic Grants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Type of Grant
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
12.4. Leading Organizations: Analysis by Number of Grants
12.5. Analysis by Type of Recipient Organization
12.6. Analysis by Administering Institute Center
12.7. Analysis by Funding Institute Center
12.8. Key Project Leaders: Analysis by Number of Grants
13. KEY COMMMERCIALIZATION STRATEGIES
13.1. Chapter Overview
13.2. Successful Drug Launch Strategy: ROOTS Framework
13.3. Successful Drug Launch Strategy: Product Differentiation
13.4. Common Commercialization Strategies Adopted Based on Development Stage of Product
13.5. Approved Molecules for ADCs
13.5.1. ADCETRIS®
13.5.2. KADCYLA®
13.5.3. MYLOTARG™
13.5.4. BESPONSA®
13.5.5. LUMOXITI™
13.5.5. POLIVY™
13.6. Key Commercialization Strategies Adopted by Companies Developing ADCs
13.6.1. Strategies Adopted Before Drug Approval
13.6.1.2. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.6.2. Strategies Adopted During / Post Drug Approval
13.6.2.1. Geographical Expansion
13.6.2.2. Participation in Global Events
13.6.2.3. Awareness Through Product Websites
13.6.2.4. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.7. Concluding Remarks
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Brochure and Informative Downloads
14.5. ADCETRIS®: Promotional Analysis
14.5.1. Product Website Analysis
14.5.1.1. Messages for Healthcare Professionals
14.5.1.2. Messages For Patients
14.5.2. Patient Support Services and Informative Downloads
14.5.3. Other Promotional Activities
14.5.3.1. Presence in Conferences
14.6. KADCYLA®: Promotional Analysis
14.6.1. Product Website Analysis
14.6.1.1. Messages for Healthcare Professionals
14.6.1.2. Messages for Patients
14.6.2. Patient Support Services and Informative Downloads
14.6.3. Other Promotional Activities
14.6.3.1. Presence in Conferences
14.7. MYLOTARG™: Promotional Analysis
14.7.1. Product Website Analysis
14.7.1.1. Messages for Healthcare Professionals
14.7.1.2. Messages for Patients
14.7.2. Patient Support Services and Informative Downloads
14.7.3. Other Promotional Activities
14.7.3.1. Presence in Conferences
14.8. BESPONSA®: Promotional Analysis
14.8.1. Product Website Analysis
14.8.1.1. Messages for Healthcare Professionals
14.8.1.2. Messages for Patients
14.8.2. Patient Support Services and Informative Downloads
14.8.3. Other Promotional Activities
14.8.3.1. Presence in Conferences
14.9. LUMOXITI™: Promotional Analysis
14.9.1. Product Website Analysis
14.9.1.1. Messages for Healthcare Professionals
14.9.1.2. Messages for Patients
14.9.2. Patient Support Services and Informative Downloads
14.9.3. Other Promotional Activities
14.9.3.1. Presence in Conferences
14.10. POLIVY™: Promotional Analysis
14.10.1. Product Website Analysis
14.10.1.1. Messages for Healthcare Professionals
14.10.1.2. Messages for Patients
14.10.2. Patient Support Services and Informative Downloads
14.10.3. Other Promotional Activities
14.10.3.1. Presence in Conferences
15. COMBINATION THERAPIES
15.1. Chapter Overview
15.2. Combination Therapy: History of Development
15.3. FDA-approved Combination Therapies in Oncology
15.4. Combination Therapy: FDA Guidelines
15.4.1. Combinations of Marketed Drugs
15.4.2. Combinations of Marketed Drugs with New Molecular Entities
15.4.3. Combinations of New Molecular Entities
15.5. Combination Therapies: ADCs
15.5.1. Completed / Ongoing Clinical Studies of ADCs
15.5.1.1. Analysis by Type of Therapy
15.5.2. Completed / Ongoing Clinical Studies of ADC-based Combination Therapies
15.5.2.1. Analysis by Highest Phase of Development
15.5.2.2. Analysis by Current Trial Status
15.5.2.3. Analysis by Type of Combination
15.5.2.4. Analysis by Indication and Type of Combination
16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
16.1. Chapter Overview
16.2. First Generation ADC Technologies
16.3. Second Generation ADC Technologies
16.3.1. Cysteine and Selenocysteine Engineering
16.3.2. Unnatural Amino Acid Engineering
16.3.3. Amino-Terminal Engineered Serine
16.4. Third Generation ADC Technologies
16.4.1. Enzyme-Assisted Ligation Approaches
16.4.2. Glycan Remodeling Approaches
16.4.3. Ligation at Fab Nucleotide-Binding Site
16.4.4. Cysteine Rebridging
16.4.5. Preventing / Limiting Retro-Michael Drug Deconjugation
16.5. Evolutionary Analysis of Conjugation Technologies
17. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
17.1. Chapter Overview
17.2. ADCs and Non-Clinical Studies
17.3. ICH S9 Guidelines
17.4. Investigational New Drug (IND)-Enabling Study Designs
17.4.1. Example Case: KADCYLA®
17.5. Toxicities in Animal Models
17.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
17.7. Other Key Considerations for Study Design
18. COST PRICE ANALYSIS
18.1. Chapter Overview
18.2. Factors Contributing Towards the High Price of ADC Therapeutics
18.3. ADC Therapeutics Market: Pricing Models
18.3.1. On the Basis of Associated Costs
18.3.2. On the Basis of Competition
18.3.3. On the Basis of Patient Segment
18.4. Reimbursement Considerations for ADC Therapeutics
19. CASE STUDY: CONTRACT MANUFACTURING OF ADC
19.1. Chapter Overview
19.2. Key Steps for ADC Manufacturing
19.3. Technical Concerns Related to ADC Manufacturing
19.4. Challenges Associated with Supply Chain and Method Transfer
19.5. Limitations of In-House Manufacturing
19.6. Investments in ADC Manufacturing Capability Expansions
19.7. Collaborations Established for ADC Manufacturing
19.8. Growing Demand for Contract Manufacturing
19.9. Emergence of Start-Ups Offering Contract Services
19.10. CMOs with Linker Manufacturing Capabilities
19.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
19.12. CMOs with Conjugation Capabilities
19.13. ADC One Stop Shops
20. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
20.1. Chapter Overview
20.1.1. Advantages of Companion Diagnostics
20.1.2. Disadvantages of Companion Diagnostics
20.2. Companion Diagnostics for ADC Therapeutics
20.3. ADC Therapeutics: List of Companion Diagnostics
20.3.1. Analysis by Type of Target
20.3.2. Analysis by Type of Cancer Indication
20.4. Concluding Remarks
21. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope and Limitations
21.3. Forecast Methodology
21.4. Overall ADC Therapeutics Market
21.4.1. ADC Therapeutics Market: Distribution by Target Indication
21.4.2. ADC Therapeutics Market: Distribution by Type of Linker
21.4.3. ADC Therapeutics Market: Distribution by Type of Payload
21.4.4. ADC Therapeutics Market: Distribution by Target Antigen
21.4.5. ADC Therapeutics Market: Distribution by Geography
21.4.6. ADC Therapeutics Market: Distribution by Technology Providers
21.5. ADC Therapeutics Market: Individual Drug Sales Forecasts
21.5.1. ADCETRIS® / Brentuximab Vedotin
21.5.1.1. Target Patient Population
21.5.1.2. Sales Forecast
21.5.2. KADCYLA® / Ado-trastuzumab Emtansine
21.5.2.1. Target Patient Population
21.5.2.2. Sales Forecast
21.5.3. MYLOTARG™ / Gemtuzumab Ozogamicin
21.5.3.1. Target Patient Population
21.5.3.2. Sales Forecast
21.5.4. BESPONSA® / Inotuzumab Ozogamicin
21.5.4.1. Target Patient Population
21.5.4.2. Sales Forecast
21.5.5. LUMOXITI™
21.5.5.1. Target Patient Population
21.5.5.2. Sales Forecast
21.5.6. POLIVYTM / Polatuzumab vedotin-piiq / RG7596
21.5.6.1. Target Patient Population
21.5.6.2. Sales Forecast
21.5.7. ASG-22ME / Enfortumab Vedotin
21.5.7.1. Target Patient Population
21.5.7.2. Sales Forecast
21.5.8. BAT8001
21.5.8.1. Target Patient Population
21.5.8.2. Sales Forecast
21.5.9. DS-8201a / DS 8201 / Trastuzumab Deruxtecan
21.5.9.1. Target Patient Population
21.5.9.2. Sales Forecast
21.5.10. IMMU-132 / Sacituzumab Govitecan
21.5.10.1. Target Patient Population
21.5.10.2. Sales Forecast
21.5.11. IMGN853 / Mirvetuximab Soravtansine
21.5.11.1. Target Patient Population
21.5.11.2. Sales Forecast
21.5.12. lpituzumab TesirineRova-T / Rova
21.5.12.1. Target Patient Population
21.5.12.2. Sales Forecast
21.5.13. SYD985 / Trastuzumab Duocarmazine
21.5.13.1. Target Patient Population
21.5.13.2. Sales Forecast
21.5.14. ABBV-399 / Teliso-V / Telisotuzumab Vedotin
21.5.14.1. Target Patient Population
21.5.14.2. Sales Forecast
21.5.15. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine
21.5.15.1. Target Patient Population
21.5.15.2. Sales Forecast
21.5.16. ADCT-402 / Loncastuximab Tesirine
21.5.16.1. Target Patient Population
21.5.16.2. Sales Forecast
21.5.17. AGS 16M8F / AGS 16C3F
21.5.17.1. Target Patient Population
21.5.17.2. Sales Forecast
21.5.18. AVID100
21.5.18.1. Target Patient Population
21.5.18.2. Sales Forecast
21.5.19. BAY 94-9343
21.5.19.1. Target Patient Population
21.5.19.2. Sales Forecast
21.5.20. GSK 2857916 / Anti-BCMA ADC
21.5.20.1. Target Patient Population
21.5.20.2. Sales Forecast
21.5.21. HuMax-TF-ADC / Tisotumab Vedotin
21.5.21.1. Target Patient Population
21.5.21.2. Sales Forecast
21.5.22. IMGN529 / Debio 1562 / Naratuximab Emtansine
21.5.22.1. Target Patient Population
21.5.22.2. Sales Forecast
21.5.23. IMMU-130 / Sacituzumab Govitecan
21.5.23.1. Target Patient Population
21.5.23.2. Sales Forecast
21.5.24. RC48
21.5.24.1. Target Patient Population
21.5.24.2. Sales Forecast
21.5.25. SGN-LIV1A / Ladiratuzumab Vedotin
21.5.25.1. Target Patient Population
21.5.25.2. Sales Forecast
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks
23. CONCLUSION
23.1. Chapter Overview
23.2. Key Takeaways
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Abzena
24.2.1. Company Snapshot
24.2.2. Interview Transcript: John Burt, Chief Executive Officer
24.3. Ajinomoto Bio-Pharma Services
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
24.4. BSP Pharmaceuticals
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.5. Catalent Pharma Solutions
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates, and Stacy McDonald, Group Product Manager
24.6. Cardiff University
24.6.1. Company Snapshot
24.6.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.7. Cerbios-Pharma
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.8. Eisai
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
24.9. Lonza
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
24.10. NBE-Therapeutics
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
24.11. Oxford BioTherapeutics
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Christian Rohlff, Chief Executive Officer and Founder
24.12. Pierre Fabre
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Christian Bailly, Director of CDMO
24.13. Piramal Healthcare
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Mark Wright, Site Head, Grangemouth
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development
24.15. Syndivia
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Sasha Koniev, Chief Executive Officer and Co-Founder
24.16. Anonymous, Director, Business Development, Leading CMO
24.17. Anonymous, Chief Executive Officer, Leading CMO
25. APPENDIX 1: TABULATED DATA
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
